Atlantic Healthcare has a committed investor base and an experienced international Board and Leadership Team, with a clear and cost-effective commercialization strategy.

We intend to commercialize our products in Europe and the U.S. using a specialist sales team targeting gastroenterologists in hospitals and specialists care centres. We plan to partner with established pharmaceutical companies to commercialize products in the rest of the world.

In the meantime, we are developing and deepening our pipeline, with additional formulations of alicaforsen for the treatment of other inflammatory bowel diseases and the recent acquisition of renzapride.

​To find out more or discuss investment opportunities, please make contact through